Pfizer liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
6.06×6.06×6.17×5.01×3.79×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
5.31×5.31×5.33×4.22×3.16×
1031034951121,823
3,1763,1762,9432,1911,836
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PFIZER₹3,759.80

Pfizer Ltd.

· Pharma & Health
₹ CrorePeersGLAXOABBOTINDIAPOLYMEDONESOURCERAINBOWKIMSJUBLPHARMAVIJAYA
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Current Ratio3.795.016.176.066.06
Quick Ratio3.164.225.335.315.31
Cash, Equiv & ST Investments1,822.9112.0495.1102.7102.7
Working Capital1,836.02,191.32,943.33,175.73,175.7
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.